AstraZeneca PLC (AZN)vsiRhythm Technologies Inc (IRTC)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
IRTC
iRhythm Technologies Inc
$111.43
-1.28%
HEALTHCARE · Cap: $4.03B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7335% more annual revenue ($61.37B vs $825.34M). AZN leads profitability with a 17.0% profit margin vs -1.7%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
IRTC
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for IRTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 20.1% year-over-year
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 19.8x book value
0.0% earnings growth
ROE of -17.2% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : IRTC
The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 20.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : IRTC
The primary concerns for IRTC are Price/Book, EPS Growth, Return on Equity. Debt-to-equity of 3.91 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while IRTC is a growth play — different risk/reward profiles.
IRTC carries more volatility with a beta of 1.32 — expect wider price swings.
IRTC is growing revenue faster at 20.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 32/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
iRhythm Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?